全文获取类型
收费全文 | 60704篇 |
免费 | 3731篇 |
国内免费 | 272篇 |
专业分类
耳鼻咽喉 | 826篇 |
儿科学 | 1467篇 |
妇产科学 | 934篇 |
基础医学 | 7196篇 |
口腔科学 | 1283篇 |
临床医学 | 6300篇 |
内科学 | 12754篇 |
皮肤病学 | 1052篇 |
神经病学 | 6119篇 |
特种医学 | 1888篇 |
外科学 | 10163篇 |
综合类 | 640篇 |
一般理论 | 70篇 |
预防医学 | 4455篇 |
眼科学 | 1273篇 |
药学 | 3664篇 |
2篇 | |
中国医学 | 59篇 |
肿瘤学 | 4562篇 |
出版年
2023年 | 256篇 |
2022年 | 474篇 |
2021年 | 1167篇 |
2020年 | 686篇 |
2019年 | 1190篇 |
2018年 | 1419篇 |
2017年 | 1087篇 |
2016年 | 1228篇 |
2015年 | 1373篇 |
2014年 | 1973篇 |
2013年 | 2760篇 |
2012年 | 4358篇 |
2011年 | 4788篇 |
2010年 | 2586篇 |
2009年 | 2414篇 |
2008年 | 4205篇 |
2007年 | 4376篇 |
2006年 | 4308篇 |
2005年 | 4318篇 |
2004年 | 4072篇 |
2003年 | 3873篇 |
2002年 | 3609篇 |
2001年 | 434篇 |
2000年 | 380篇 |
1999年 | 535篇 |
1998年 | 724篇 |
1997年 | 593篇 |
1996年 | 532篇 |
1995年 | 517篇 |
1994年 | 424篇 |
1993年 | 361篇 |
1992年 | 291篇 |
1991年 | 229篇 |
1990年 | 218篇 |
1989年 | 165篇 |
1988年 | 216篇 |
1987年 | 175篇 |
1986年 | 181篇 |
1985年 | 189篇 |
1984年 | 216篇 |
1983年 | 236篇 |
1982年 | 323篇 |
1981年 | 293篇 |
1980年 | 227篇 |
1979年 | 97篇 |
1978年 | 129篇 |
1977年 | 114篇 |
1976年 | 69篇 |
1974年 | 54篇 |
1973年 | 52篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
991.
992.
993.
Toshio Tsuyuguchi Tadahiro Takada Yoshifumi Kawarada Yuji Nimura Keita Wada Masato Nagino Toshihiko Mayumi Masahiro Yoshida Fumihiko Miura Atsushi Tanaka Yuichi Yamashita Masahiko Hirota Koichi Hirata Hideki Yasuda Yasutoshi Kimura Horst Neuhaus Steven Strasberg Henry Pitt Jacques Belghiti Giulio Belli John A. Windsor Miin-Fu Chen Sun-Whe Kim Christos Dervenis 《Journal of hepato-biliary-pancreatic sciences》2007,14(1):46-51
The principal management of acute cholecystitis is early cholecystectomy. However, percutaneous transhepatic gallbladder drainage (PTGBD) may be preferable for patients with moderate (grade II) or severe (grade III) acute cholecystitis. For patients with moderate (grade II) disease, PTGBD should be applied only when they do not respond to conservative treatment. For patients with severe (grade III) disease, PTGBD is recommended with intensive care. Percutaneous transhepatic gallbladder aspiration (PTGBA) is a simple alternative drainage method with fewer complications; however, its clinical usefulness has been shown only by case-series studies. To clarify the clinical value of these drainage methods, proper randomized trials should be done. This article describes techniques of drainage for acute cholecystitis. 相似文献
994.
Daoud EG Weiss R Augostini RS Kalbfleisch SJ Schroeder J Polsinelli G Hummel JD 《Journal of cardiovascular electrophysiology》2002,13(1):20-24
INTRODUCTION: The purpose of this study was to investigate the effect of ablation of right atrial flutter upon sinus node function in humans. METHODS AND RESULTS: This study enrolled 35 patients. Twenty-four patients (16 men and 8 women; age 68 +/- 11 years) were referred for ablation of persistent atrial flutter (duration 8 +/- 11 months). After ablation, there was abnormal sinus node function defined as a corrected sinus node recovery time (CSNRT) > or = 550 msec. The control group consisted of 11 patients who were undergoing pacemaker implantation for sinus node disease but did not have a history of atrial dysrhythmias or ablation. Within 24 hours of ablation or pacemaker implantation, baseline maximal CSNRT was measured through a permanent pacemaker by AAI pacing at six cycle lengths: 600, 550, 500, 450, 400, and 350 msec. CSNRT then was measured in the same manner at 48 hours, 14 days, and 3 months after ablation/pacemaker implantation. P wave amplitude and duration, and percent atrial sensing also were assessed at the same intervals. For patients undergoing atrial flutter ablation, there was progressive temporal recovery of CSNRT (1,204 +/- 671 msec at baseline vs 834 +/- 380 msec at 3 months; P < 0.001) and a significant increase in the percent atrial sensing and P wave amplitude at 3 months compared with baseline (P < 0.001). In control subjects, there was no change in the CSNRT, percent atrial pacing, or P wave amplitude. CONCLUSION: After ablation of persistent atrial flutter, there is temporal recovery of CSNRT and increase in spontaneous atrial activity. These findings suggest that atrial flutter induces reversible changes in sinus node function. 相似文献
995.
Metabolically controlled reperfusion in acute myocardial infarction: should the polarizing solution be given subselectively? 总被引:2,自引:0,他引:2
Angelini P Haas PC Bucciarelli Ducci C Adams S Ober J Bigley J Clubb FJ Frazier OH 《The Journal of invasive cardiology》2003,15(9):491-496
BACKGROUND: In working rat hearts, metabolic support of injured tissue enhances recovery after acute myocardial infarction. Clinical experience with a systemic "polarizing solution" supports this claim. OBJECTIVES: In a dog model of ischemia/reperfusion, we tested the feasibility of subselectively supplying adapted metabolic substrates before instituting blood reperfusion. METHODS: Thirty-five dogs underwent ligation of the proximal left anterior descending artery and collaterals for 90 minutes. The animals were randomly assigned to receive direct blood reperfusion (Group I), intracoronary glucose, insulin, and potassium (Group II), or intracoronary glucose, insulin, and potassium plus propionyl-L-carnitine (PLC) (Group III). After 30 minutes of artificial reperfusion, prograde blood flow was resumed in groups II and III. A routine necropsy was performed 3 to 5 days later. Primary endpoints were severe arrhythmias, death, markers of infarct size, and specific histologic features. RESULTS: We excluded 4 dogs for technical reasons and 2 others for preexisting cardiomyopathy. In the remaining 29 animals, large apical infarctions were documented ventriculographically during arterial ligation. One dog died of irreversible ventricular fibrillation during the initial ischemic period, and 9/28 dogs (32.1%) died during early reperfusion. Ventricular fibrillation was more common with 10% (versus 5%) dextrose concentrations and was eliminated by PLC. Irreversibly injured (versus jeopardized) areas of myocardium were more common in Group III (85.9 19.3%) than in Groups I and II (16.9 10.8%). CONCLUSION: Subselective infusion of metabolically supportive solutions during acute myocardial infarction is technically feasible. To prevent osmotic endothelial damage, the perfusate must have a low (< 5%) dextrose content. 相似文献
996.
BACKGROUND: Most patients with hypertension require more than one agent to control blood pressure (BP). The purpose of this study was to assess the efficacy and safety of the angiotensin II receptor blocker olmesartan medoxomil in combination with hydrochlorothiazide (HCTZ). METHODS: This was a randomized, double-blind, factorial design study. After a placebo run-in period, eligible patients (n = 502) with a baseline mean seated diastolic blood pressure (SeDBP) of 100 to 115 mm Hg were randomized to one of 12 groups: placebo, olmesartan medoxomil monotherapy (10, 20, or 40 mg/day, HCTZ monotherapy (12.5 or 25 mg/day), or one of six groups of olmesartan medoxomil/HCTZ combination therapy. The primary endpoint was the change in mean trough SeDBP from baseline at week 8. Statistical analyses were conducted to determine whether at least one combination produced a larger reduction in SeDBP at week 8 than the individual corresponding component doses, but did not compare BP reductions with different combination doses. RESULTS: Olmesartan medoxomil plus HCTZ produced greater reductions in both SeDBP and seated systolic blood pressure (SeSBP) at week 8 than did monotherapy with either component. All olmesartan medoxomil/HCTZ combinations significantly reduced SeDBP and SeSBP compared with placebo in a dose-dependent manner. Reductions from baseline in mean trough SeSBP/SeDBP were 3.3/8.2 mm Hg, 20.1/16.4 mm Hg, and 26.8/21.9 mm Hg with placebo, olmesartan medoxomil/HCTZ 20/12.5 mg, and olmesartan medoxomil/HCTZ 40/25 mg, respectively. All treatments were well tolerated. CONCLUSIONS: Olmesartan medoxomil/HCTZ combination therapy produced BP reductions of up to 26.8/21.9 mm Hg and was well tolerated. 相似文献
997.
998.
999.
1000.
Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age 总被引:2,自引:0,他引:2
Ettinger MP Felsenberg D Harris ST Wasnich R Skag A Hiltbrunner V Wilson K Schimmer RC Miller PD 《The Journal of rheumatology》2005,32(10):1968-1974
OBJECTIVE: The risk of osteoporosis increases exponentially with age. Elderly patients, who are often frail, have declining functional status and take multiple medications, and require osteoporosis therapies that are not only effective, but also very well tolerated. Ibandronate is a potent nitrogen-containing bisphosphonate that can be given intermittently with extended between-dose intervals. Oral daily and intermittent ibandronate (interval between doses > 2 mo) was found to significantly reduce the risk of new morphometric vertebral fractures by 62% and 50%, respectively, compared with calcium and vitamin D supplementation alone. We investigated the effect of age on the safety profile of oral daily and intermittent ibandronate, with particular emphasis on the upper gastrointestinal (GI) safety profile of ibandronate. METHODS: A predefined subgroup analysis examined the tolerability of oral ibandronate in women aged < 70 and > or = 70 years. RESULTS: The incidence of adverse events in patients aged > or = 70 years receiving oral daily and intermittent ibandronate was similar and comparable to placebo. The incidence of upper GI adverse events, including dyspepsia and esophagitis, was also similar between the 2 treatment groups and placebo. CONCLUSION: Older patients (> or = 70 yrs) receiving oral daily and intermittent ibandronate are at no greater risk of adverse events than older patients receiving placebo. Older patients were at no greater risk of upper GI adverse events than younger patients or patients receiving placebo. As a result of the good efficacy and tolerability observed in this trial, a once-monthly oral regimen of ibandronate is in late-stage clinical development. 相似文献